Is AstraZeneca (LSE:AZN) Undervalued On Its Recent FDA Approvals And Phase III Data?

AstraZeneca (LSE:AZN) just packed three meaningful drug milestones into a short window, including US accelerated approvals for ZEGFROVY in a lung cancer niche and Ultomiris in IgA nephropathy, plus strong Phase III TEZSPIRE data.

The latest approvals and data have landed against a mixed backdrop for AstraZeneca. The 1-day share price return of 2.9% lifted the stock to £129.80 and recent drug news has supported a 1-year total shareholder return of 5.65%, even as the year-to-date share price return is still down 4.5%.

Scan the AstraZeneca headlines, then size up similarly research-heavy pharma players using our curated list of 5 high quality undiscovered gems as a starting universe.

AstraZeneca now trades higher after the flurry of drug news, yet the larger debate still hangs over it. Has the recent rerating already captured the good news, or does the valuation still leave room for more?

Most Popular Narrative: 18% Undervalued

AstraZeneca’s most followed valuation narrative pegs fair value at £159.11, comfortably above the £129.80 last close, which frames the recent drug wins as only part of a wider rerating story.

The company's robust and diversified late-stage pipeline, particularly in oncology, rare diseases, and cardiovascular/metabolic therapies, is set to deliver multiple blockbuster launches over the next several years. Management estimates these new medicines could generate $10+ billion in peak risk-adjusted revenue, directly supporting both long-term high-margin revenue growth and future earnings expansion.

See why 214 investors see AstraZeneca as 18% undervalued.

Result: Fair Value of £159.11 (UNDERVALUED)

Still, AstraZeneca’s reliance on a handful of blockbuster drugs and rising exposure to price controls could quickly challenge that narrative of being 18% undervalued.

Find out about the key risks to this AstraZeneca narrative.

Next Steps

Mixed signals on AstraZeneca so far, right? If you want to move beyond the headline take, weigh both sides of the story yourself and then check the 4 key rewards and 1 important warning sign.

Looking for more AstraZeneca investment ideas?

Do not stop with AstraZeneca. Broaden your watchlist with data driven shortlists that surface new opportunities before they hit everyone else's radar.

• Target potential value upside by scanning companies trading on compelling fundamentals with the 7 high quality undervalued stocks.
• Prioritise resilience by filtering for businesses with stronger finances and healthier leverage profiles using the list of solid balance sheet and fundamentals (9 results).
• Hunt for steady income streams by reviewing companies in the 4 dividend fortresses that offer higher yields, with screening focused on quality.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com